Preferential mRNA Expression of HOXC4, HOXC5, and HOXC6 in T-NHL and B-NHL Originating in Specific Body Sites, Using RISH, and Comparisons of HOXC5 Expression in Lymphomas According to Histological Type and in Site of Origin
| . | T-NHL . | . | B-NHL . | ||||
|---|---|---|---|---|---|---|---|
| . | C4 . | C5 . | C6 . | . | C4 . | C5 . | C6 . |
| Oro-digestive tract | 7/83-150 | 2/6 | 6/8 | Oro-digestive tract | 13/14 | 8/15 | 14/15 |
| ALCL | 1/1 | — | 1/1 | Maltomas | 7/8 | 6/8 | 7/8 |
| PTCL | 6/7 | 2/6 | 5/7 | Other | 6/6 | 2/7 | 7/7 |
| Skin | 16/18 | 9/17 | 18/18 | Skin | 6/6 | 0/6 | 6/6 |
| ALCL | 9/9 | 9/9 | 9/9 | ||||
| Other | 8/9 | 0/8 | 9/9 | ||||
| LN | 15/17 | 3/16 | 17/17 | LN | 22/22 | 3/21 | 15/21 |
| ALCL | 7/9 | 3/8 | 9/9 | Immunocytomas | 6/6 | 2/5 | 4/5 |
| Other | 8/8 | 0/8 | 8/8 | Other | 16/16 | 1/16 | 11/16 |
| Spleen | 1/1 | 0/1 | 1/1 | ||||
| Bone marrow | 1/1 | 1/1 | 1/1 | ||||
| . | T-NHL . | . | B-NHL . | ||||
|---|---|---|---|---|---|---|---|
| . | C4 . | C5 . | C6 . | . | C4 . | C5 . | C6 . |
| Oro-digestive tract | 7/83-150 | 2/6 | 6/8 | Oro-digestive tract | 13/14 | 8/15 | 14/15 |
| ALCL | 1/1 | — | 1/1 | Maltomas | 7/8 | 6/8 | 7/8 |
| PTCL | 6/7 | 2/6 | 5/7 | Other | 6/6 | 2/7 | 7/7 |
| Skin | 16/18 | 9/17 | 18/18 | Skin | 6/6 | 0/6 | 6/6 |
| ALCL | 9/9 | 9/9 | 9/9 | ||||
| Other | 8/9 | 0/8 | 9/9 | ||||
| LN | 15/17 | 3/16 | 17/17 | LN | 22/22 | 3/21 | 15/21 |
| ALCL | 7/9 | 3/8 | 9/9 | Immunocytomas | 6/6 | 2/5 | 4/5 |
| Other | 8/8 | 0/8 | 8/8 | Other | 16/16 | 1/16 | 11/16 |
| Spleen | 1/1 | 0/1 | 1/1 | ||||
| Bone marrow | 1/1 | 1/1 | 1/1 | ||||
| Type-specificity | Type-specificity | ||
| ALCL† v other T-NHL | P < .0013-152 | B-NHL with lymphoplasmacytic differentiationρ v other B-NHL | P = .001 |
| Site-specificity | Site-specificity | ||
| T-NHL skin v T-NHL other sites | P = NS | B-NHL oro-digestive tract v B-NHL other sites | P = .014 |
| ALCL skin v nodal ALCL | P = .009 | Maltomas v nodal immunocytomas | P = NS |
| Combined type- and site-specificity | Combined type- and site-specificity | ||
| ALCL skin v other T-NHL | P < .001 | Maltomas v other B-NHL | P < .001 |
| Nodal ALCL v other nodal T-NHL | P = NS | Nodal immunocytomas v other nodal B-NHL | P = NS |
| Type-specificity | Type-specificity | ||
| ALCL† v other T-NHL | P < .0013-152 | B-NHL with lymphoplasmacytic differentiationρ v other B-NHL | P = .001 |
| Site-specificity | Site-specificity | ||
| T-NHL skin v T-NHL other sites | P = NS | B-NHL oro-digestive tract v B-NHL other sites | P = .014 |
| ALCL skin v nodal ALCL | P = .009 | Maltomas v nodal immunocytomas | P = NS |
| Combined type- and site-specificity | Combined type- and site-specificity | ||
| ALCL skin v other T-NHL | P < .001 | Maltomas v other B-NHL | P < .001 |
| Nodal ALCL v other nodal T-NHL | P = NS | Nodal immunocytomas v other nodal B-NHL | P = NS |
Abbreviations: PTCL, pleomorphic T-cell lymphoma; LN, lymph node; NS, not significant.
Positive/total number of lymphomas tested.
Includes only ALCL derived from skin and LN.
Determined with Fisher's exact test.
ρ Lymphomas with plasmacytic differentiation are maltomas and immunocytomas.